VGTI Florida to Collaborate with TapImmune to Advance Targeted Breast and Ovarian Cancer Vaccines into Phase II Clinical Trials

VGTI Florida to coordinate cancer study design and trial sites selection November 18, 2014 The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, today announced a new collaborative research agreement with TapImmune, Inc., forming a partnership to advance TapImmune’s proprietary, targeted cancer vaccines into mid-stage, Phase II human clinical trials for the treatment …

VGTI Florida Aims to Stop Spread of Chikungunya Virus with Novel Vaccine

No licensed vaccine exists for mosquito-borne threat that has reached U.S. Virus-like particle platform technology could also target Ebola virus Scheduled to exhibit at Military Health System Research Symposium August 11, 2014 It’s another soaking wet rainy season in South Florida, and with it comes ideal conditions for mosquitos to breed and thrive, but this summer brings fears beyond just …

VGTI Florida Researcher Invents Potential Breakthrough Antiviral Compounds for Prevention of Mosquito-Borne Illnesses

July 28th, 2014 The Vaccine & Gene Therapy Institute of Florida (VGTI Florida) a leading non-profit biomedical research institute today announced a key milestone achievement in developing novel approaches for the prevention of mosquito-borne viral threats including chikungunya and dengue fever diseases that are currently epidemic in tropical regions of the world and now represent serious threats to the U.S. …